This study is currently not recruiting participants.

A Phase III Randomized Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft-Versus-Host Disease (GVHD) Prophylaxis After HLA-Matched Related Peripheral Blood Stem Cell Transplantation

Investigating Medication Combinations for Preventing Graft-Versus-Host Disease (a post-transplant complication)

Not Recruiting
18 years - 60 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to compare two combinations of medications to see which is better at preventing Graft-Versus-Host-Disease.

Detailed description of study

The purpose of this study is to compare two combinations of medications to see which is better at preventing Graft-Versus-Host-Disease.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Leukemia
  • Age: 18 years - 60 years
  • Gender: All

The purpose of this study is to compare two combinations of medications to see which is better at preventing Graft-Versus-Host Disease. Graft-Versus-Host Disease is a condition that can occur after a transplant, where the donated cells attack the recipient's body.

Participants in this study will receive one of the two medication combinations. The study will monitor the effectiveness of these combinations in preventing Graft-Versus-Host Disease.

  • Who can participate: Eligibility criteria include age range of 18-65 years and individuals who have undergone or are scheduled for a transplant. Further eligibility factors may apply.
  • Study details: Participants will receive one of the two medication combinations being studied. The study will observe the effects of these combinations on preventing Graft-Versus-Host Disease.
Updated on 19 Feb 2024. Study ID: 1105005632

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team